Betaseron
(Interferon beta-1b)PreclinicalSmall molecule
BayerInterferon beta-1b is used to treat multiple sclerosis, a disease where the immune system attacks nerve fibers in the brain and spinal cord, causing problems with movement and other functions. It helps reduce the frequency and severity of relapses in relapsing-remitting MS.[1] Betaseron is currently being investigated across 2 indications[3], with its most advanced program in Preclinical.[1]
Betaseron is one of 8 small molecule programs targeting Chronic Progressive Multiple Sclerosis. It is currently in Preclinical.
2
Indications
48
Total Trials
0
Active Trials
7
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Chronic Progressive Multiple Sclerosis
#DrugCompanyPhaseTrials
1Tecfidera
BiogenApproved
Plaquenil
Jazz PharmaceuticalsApproved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Leustatin
EMD SeronoApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ocrevus
RochePreclinical
Betaseron
BayerPreclinical
BRIUMVI
TTG Therapeutics, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Multiple Sclerosis16 trials
Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis
Completed·—··NCT00490906·60 enrolled
Show 13 more trials
Relapsing-Remitting Multiple Sclerosis4 trials
COVID-194 trials
14 more indications
Cardiomyopathy1 trial
Observational Study1 trial
Patient Satisfaction1 trial
Quality of Life1 trial
Prospective1 trial
Satisfaction1 trial
RRMS1 trial
Safety and Efficacy1 trial
Cytomegalovirus (CMV)1 trial
Unspecified8 trials
Regulatory
FDA Approval Timeline[4]
Jul 23, 1993
BETASERON
BLA BLA103471
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Interferon beta-1b. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]